Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor.
Topical roflumilast, 0.05%, is under consideration for treating mild to moderate atopic dermatitis in children aged 2-5 years ...
Unlike other phosphodiesterase-4 inhibitors on the market, PALI-2108 is a new chemical entity and is being administered to humans for the first time. To gain insights into the therapy’s effects ...
The cyclic nucleotide phosphodiesterase 4 (PDE4) regulates the hydrolysis of the second messenger cyclic AMP. cAMP is a major intracellular signalling mediator that directly affects the activity ...
This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic dermatitis (AD) in children aged 2 to 5 years. The PDUFA target action date of ...
Alto Neuroscience, Inc.’s ANRO share price has dipped by 10.13%, which has investors questioning if this is right time to buy ...
The Californian company earlier announced the US Food and Drug Administration’s (FDA) acceptance of a supplemental New Drug ...
Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback